Nutrients 5 , 9811001 (2013)
In certain conditions where neutropenia is expected, such as chemotherapy, granulocyte colony-stimulating factors (eg, filgrastim [Neupogen]) and/or granulocyte macrophage colony-stimulating factors (eg, sargramostim [Leukine]) can be used as a preventive measure (Renner 2012)
in relation to its major active constituent curcumin
This pharmacological profile creates a dose-dependent weight loss curve that, in clinical trials, reached 24.2% at the 12mg weekly dose over 48 weeks and an astonishing 28.7% at 12mg over 68 weeks in the TRIUMPH-4 phase 3 trial
The inconsistency in prior research likely results from key methodological issues
This commitment to consistency is a core part of our results-oriented approach